253 related articles for article (PubMed ID: 26902424)
1. Tumor heterogeneity and circulating tumor cells.
Zhang C; Guan Y; Sun Y; Ai D; Guo Q
Cancer Lett; 2016 May; 374(2):216-23. PubMed ID: 26902424
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumour cells: insights into tumour heterogeneity.
Hayes DF; Paoletti C
J Intern Med; 2013 Aug; 274(2):137-43. PubMed ID: 23844916
[TBL] [Abstract][Full Text] [Related]
3. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
[TBL] [Abstract][Full Text] [Related]
4. Genetic traits for hematogeneous tumor cell dissemination in cancer patients.
Joosse SA; Pantel K
Cancer Metastasis Rev; 2016 Mar; 35(1):41-8. PubMed ID: 26931653
[TBL] [Abstract][Full Text] [Related]
5. Single circulating tumor cell sequencing as an advanced tool in cancer management.
Salvianti F; Pazzagli M; Pinzani P
Expert Rev Mol Diagn; 2016; 16(1):51-63. PubMed ID: 26560087
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells: a multifunctional biomarker.
Yap TA; Lorente D; Omlin A; Olmos D; de Bono JS
Clin Cancer Res; 2014 May; 20(10):2553-68. PubMed ID: 24831278
[TBL] [Abstract][Full Text] [Related]
7. Using CTCs for pharmacogenomic analysis.
Hart CD; Galardi F; Pestrin M; De Luca F; Risi E; Di Leo A
Pharmacol Res; 2016 Apr; 106():92-100. PubMed ID: 26921662
[TBL] [Abstract][Full Text] [Related]
8. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
[TBL] [Abstract][Full Text] [Related]
9. Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine.
Alberter B; Klein CA; Polzer B
Expert Rev Mol Diagn; 2016; 16(1):25-38. PubMed ID: 26567956
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration.
Hwang WL; Pleskow HM; Miyamoto DT
Adv Drug Deliv Rev; 2018 Feb; 125():122-131. PubMed ID: 29326053
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and consequences of heterogeneity in the circulating tumor cell compartment.
Brouwer A; De Laere B; Peeters D; Peeters M; Salgado R; Dirix L; Van Laere S
Oncotarget; 2016 Jul; 7(30):48625-48643. PubMed ID: 26980749
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic potential of mutation detection from single circulating tumor cells in cancer patients.
Salvianti F; Pinzani P
Expert Rev Mol Diagn; 2017 Nov; 17(11):975-981. PubMed ID: 28931314
[TBL] [Abstract][Full Text] [Related]
13. Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications.
Danova M; Torchio M; Mazzini G
Expert Rev Mol Diagn; 2011 Jun; 11(5):473-85. PubMed ID: 21707456
[TBL] [Abstract][Full Text] [Related]
14. Overview of current standpoints in profiling of circulating tumor cells.
Kim K; Lee KH; Lee J; Choi J
Arch Pharm Res; 2014 Jan; 37(1):88-95. PubMed ID: 24214218
[TBL] [Abstract][Full Text] [Related]
15. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy.
Paterlini-Bréchot P
Future Oncol; 2011 Jul; 7(7):849-71. PubMed ID: 21732757
[TBL] [Abstract][Full Text] [Related]
16. Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures.
Kanwar N; Done SJ
Adv Exp Med Biol; 2017; 994():143-167. PubMed ID: 28560673
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells as promising novel biomarkers in solid cancers.
Lianidou ES; Strati A; Markou A
Crit Rev Clin Lab Sci; 2014 Jun; 51(3):160-71. PubMed ID: 24641350
[TBL] [Abstract][Full Text] [Related]
18. Classifying circulating tumor cells to monitor cancer progression.
Economopoulou P; Georgoulias V; Kotsakis A
Expert Rev Mol Diagn; 2017 Feb; 17(2):153-165. PubMed ID: 28032524
[TBL] [Abstract][Full Text] [Related]
19. Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis.
Tellez-Gabriel M; Ory B; Lamoureux F; Heymann MF; Heymann D
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999407
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathology in real time.
Ryška A
Cancer Metastasis Rev; 2016 Mar; 35(1):129-40. PubMed ID: 26931654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
